

Point-by-point response

We thank the reviewers and Editors for their interest in our perspective and suggestions to improve its quality. We have considered and responded to each of the points raised by reviewer #1 (Reviewer #2 did not raise any concern). We have also responded to all the comments of the Editors. We feel these changes have significantly improved the quality of the commentary and we hope that it is now acceptable for publication. The changes are highlighted in blue in the revised copy and briefly detailed below:

1) *Can the authors present the major clinical trials conducted on T1D, including the treatment, major findings, rationales (the studies on NOD mice and reference) and the clinical results, in a tabular format?*

Response. There have been several excellent reviews of major trials by leaders in the field in the last two years. So we have referred the readers to these reviews. However, if the reviewer feels strongly about addition of such a Table, we would be happy to comply.

2) *The authors should provide the full name of the nPOD, its funding agency, their website and ways to get involved.*

Response. We have now included the requested information (p. 3).

3) *The authors should give some examples of new findings from nPOD-supported studies, especially those that can potentially cause paradigm changes in T1D research. This should also be done in tabular format.*

Response. In response to this suggestion, we have pointed to pancreas as the organ where major differences between the NOD mouse and humans are found. For summary of major findings as viewed by leaders of nPOD, we referred the readers to two recent articles by Atkinson et al (Diabetes care, 2015) and Pugliese et al (Pediatric diabetes, 2014) that describe these findings.

4) *Please revise the second last sentence of the first paragraph in Page 3. It is a collaborative scientific effort. Please delete "wild science-fiction dream".*

Response. As requested the sentence has been changed.

5) *The last sentence of the first paragraph: please specify, in more detail, how humanized mice can be integrated in the nPOD program for T1D research.*

Response. Has been detailed as requested (p. 3).